Table 3.
Association between HAA intake and prostate cancer
| Mean (SD) | Cases | Controls | OR (95% CI)a | |
|---|---|---|---|---|
| Total HAAs (ng/day) | ||||
| Low tertile | 17.5 (7.1) | 100 | 131 | 1.00 |
| Moderate tertile | 35.6 (5.3) | 108 | 124 | 1.14 (0.83–1.58) |
| High tertile | 72.9 (29.2) | 143 | 96 | 1.90 (1.40–2.59) |
| Trend Pb | < 0.001 | |||
| Total Trp-P-1 (ng/day) | ||||
| Low tertile | 0.44 (0.55) | 104 | 129 | 1.00 |
| Moderate tertile | 2.9 (0.55) | 104 | 128 | 1.05 (0.76–1.45) |
| High tertile | 7.2 (5.0) | 143 | 94 | 1.92 (1.42–2.61) |
| Trend P | < 0.001 | |||
| Total MeIQ (ng/day) | ||||
| Low tertile | 2.3 (0.93) | 100 | 131 | 1.00 |
| Moderate tertile | 4.5 (0.57) | 109 | 123 | 1.18 (0.85–1.63) |
| High tertile | 9.0 (3.7) | 142 | 97 | 1.87 (1.38–2.55) |
| Trend P | < 0.001 | |||
| Total MeIQx (ng/day) | ||||
| Low tertile | 2.4 (0.98) | 99 | 132 | 1.00 |
| Moderate tertile | 4.9 (0.71) | 102 | 130 | 1.05 (0.76–1.46) |
| High tertile | 9.9 (3.9) | 150 | 89 | 2.25 (1.65–3.06) |
| Trend P | < 0.001 | |||
| Total PhIP (ng/day) | ||||
| Low tertile | 10.5 (4.2) | 102 | 129 | 1.00 |
| Moderate tertile | 21.5 (3.2) | 106 | 126 | 1.06 (0.77–1.48) |
| High tertile | 44.7 (18.3) | 143 | 96 | 1.84 (1.35–2.50) |
| Trend P | < 0.001 | |||
BMI body mass index; OR oratio; 95% CI 95% confidence interval; HAA heterocyclic aromatic amine; Trp-P-1 3-Amino-1, 4-dimethyl-5H-pyrido[4, 3-b]indole; MeIQ 2-Amino-3,4-dimethylimidazo[4,5-f]quinoline; MeIQx 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
aORs (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake
b P value for Cochran–Armitage test for trend